From 23 June, people living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings. This does not mean prescriptions will be provided immediately. It means primary care settings can begin discussions with patients about whether tirzepatide is the right option to improve their health through weight loss.
Access is prioritised for those with the greatest clinical need, it’s for people living with obesity, in poor health with multiple obesity related conditions; as they would benefit most from the treatment.
Full qualifying criteria is a BMI (Body Mass Index) of 40 or greater and four or more of the following diagnosed health conditions:
✓ type 2 diabetes
✓ Hypertension
✓ Cardiovascular disease
✓ Obstructive sleep apnoea
✓ Dyslipidaemia
Weight management services are locally commissioned and funded at an Integrated Care Board (ICB) level, which means services will differ across each ICB.
Find out more:
Weight management in Greater Manchester | Greater Manchester Integrated Care Partnership